New hope for hard-to-treat leukemia: experimental drug enters final testing phase
NCT ID NCT07489755
First seen Mar 24, 2026 · Last updated May 06, 2026 · Updated 7 times
Summary
This study tests a new drug called TGRX-678 in people with chronic myeloid leukemia (CML) whose cancer has stopped responding to or caused side effects from at least three prior treatments. About 180 adults will receive either TGRX-678 or another standard drug chosen by their doctor. The main goal is to see if TGRX-678 can delay disease progression or death better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA - CHRONIC PHASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.